BioNTech SE
NASDAQ:BNTXBiotechnology
-$1.41 today
- Market cap
- $20.64B
- Beta
- 1.32
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$4.93
Volume 1.24M
Average 1.11M
BNTX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
BioNTech SENASDAQ: BNTX
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of €266.1M rose 421.8% year over year, ahead of the +122.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 115.8% from the prior quarter. Over 3 fiscal years it compounded at +43.9% a year.
Context
- Depreciation & amortization amounted to 13.3% of revenue in FY2025, up 2.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +421.8% holds above the trailing-twelve-month pace of +122.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the income statement
- Latest · FY2025
- 367.69M EUR
- Year-over-year change
- +23.4%
- 4-year CAGR
- +48.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 367.69M | +23.4% |
| FY2024 | 2024-12-31 | 298M | +62.5% |
| FY2023 | 2023-12-31 | 183.4M | +48.7% |
| FY2022 | 2022-12-31 | 123.3M | +64.0% |
| FY2021 | 2021-12-31 | 75.2M | — |
Depreciation & Amortization vs competitors
How BNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +122.9% is the highest of 9, against a peer median of -3.8%.
- Depreciation & amortization amounts to 25.6% of revenue for BNTX, versus a peer median of 3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €676.85M EUR | +122.9% | +43.9% | 25.6% | |
| LTM Jun 2026 | $98.28M USD | +8.6% | +11.2% | 1.7% | |
| LTM Jun 2026 | $44M USD | — | -41.9% | 1.1% | |
| LTM Sep 2026 | $42.96M USD | -7.4% | +30.8% | 11.3% | |
| LTM Sep 2026 | $16.54M USD | +4.6% | -5.3% | 9.1% | |
| LTM Mar 2026 | €12.04M EUR | -2.6% | +21.9% | 32.3% | |
| LTM Jun 2026 | $10.17M USD | -10.7% | +6.1% | 9.7% | |
| LTM Mar 2026 | $7.09M USD | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $3.14M USD | -22.4% | -18.0% | 0.8% | |
| LTM Sep 2026 | $316K USD | +32.2% | -22.0% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | -0.5% | 0.0% | |
| Peer median (excluding BNTX) | — | -3.8% | -2.9% | 3.1% | |
Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.98B | 17.31B | 3.82B | 2.75B | 2.76B |
| Cost of Revenue | 2.91B | 3B | 599.8M | 541.3M | 616.47M |
| Gross Profit | 16.07B | 14.32B | 3.22B | 2.21B | 2.14B |
| Gross Margin | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| Research & Development | 949.2M | 1.54B | 1.78B | 2.25B | 2.02B |
| Selling, General & Admin | 327.2M | 541.2M | 557.7M | 599M | 698.2M |
| Operating Expenses | 781.4M | 1.67B | 2.53B | 3.52B | 2.76B |
| Depreciation & Amortization | 75.2M | 123.3M | 183.4M | 298M | 367.69M |
| EBITDA | 15B | 13.1B | 1.38B | (367.1M) | (628M) |
| EBITDA Margin | 79.1% | 75.7% | 36.1% | -13.3% | -22.8% |
| Operating Income | 15.28B | 12.64B | 690.4M | (1.31B) | (623.87M) |
| Operating Margin | 80.5% | 73.0% | 18.1% | -47.8% | -22.6% |
| Interest Income | 1.56M | 47.37M | 351.31M | 0 | 252.24M |
| Interest Expense | 5.63M | 15.82M | 7.76M | 13.16M | 13.64M |
| Other Income / Expenses | (237.4M) | 311.4M | 495.7M | 636.6M | (385.46M) |
| Income Before Tax | 15.05B | 12.95B | 1.19B | (677.7M) | (1.01B) |
| Pre-Tax Margin | 79.3% | 74.8% | 31.1% | -24.6% | -36.6% |
| Income Tax Expense | 4.75B | 3.52B | 255.8M | (12.4M) | 81.93M |
| Net Income | 10.29B | 9.43B | 930.3M | (665.3M) | (1.09B) |
| Net Margin | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| EPS (Basic) | 43.87 | 38.08 | 3.87 | (2.77) | (4.51) |
| EPS (Diluted) | 41.21 | 37.09 | 3.83 | (2.77) | (4.51) |
| Weighted Avg Shares | 244M | 243.3M | 240.6M | 240.4M | 241.7M |
| Weighted Avg Shares (Diluted) | 259.7M | 249.8M | 242.7M | 240.4M | 241.7M |
BioNTech SE
NASDAQ:BNTX
Intrinsic Alpha fair value
Locked
Current Price
$83.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.